Expression of Glut-1 and HK-II in Pancreatic Cancer and Their Impact on Prognosis and FDG Accumulation.

Transl Oncol

Department of Gastroenterology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China. Electronic address:

Published: December 2016

Objective: The purpose of this article is to analyze the expression of Glut-1 and HK-II, the association between their expression and F-FDG accumulation in pancreatic cancer.

Methods: Fifty patients with histologically proven pancreatic cancer were included in this preliminary study, all of whom received F-FDG PET/CT performance before surgery. Immunohistochemical staining of tumor tissue and adjacent normal tissue was performed for Glut-1 and HK-II. By combining proportions and intensity of immunochemical staining, we obtained the modified immunohistological scores for Glut-1 and HK-II respectively. The relationship between expression of Glut-1, HK-II and series of parameters was analyzed, i.e. clinicopathological characteristics, prognosis of patients and SUV of PET-CT.

Results: Compared with normal tissue, the Glut-1 and HK-II expression in pancreatic cancer tissue was significantly increased (P<.001). There was no correlation between expression of Glut-1, HK-II and age, gender, tumor size, tumor location, tumor histological type, tumor differentiation, the nerve infiltration, vascular invasion, local infiltration, lymph node metastasis or tumor staging in pancreatic cancer (P>.05). During the follow-up period, the survival curves of low Glut-1 group and high Glut-1 group were statistically different (P=.049). Multivariate analysis (Cox regression) revealed that Glut-1 expression was not associated with mortality (P>.05). No statistical difference was found in the survival curves of negative HK-II group and positive HK-II group (P=.545). There was no correlation between F-FDG uptake and expression of Glut-1 and HK-II(P>.05).

Conclusion: The Glut-1 and HK-II expression in pancreatic cancer tissue was significantly increased. There was no correlation between expression of Glut-1, HK-II and clinicopathological characteristics, prognosis and F-FDG uptake.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143352PMC
http://dx.doi.org/10.1016/j.tranon.2016.08.004DOI Listing

Publication Analysis

Top Keywords

glut-1 hk-ii
32
expression glut-1
20
pancreatic cancer
16
glut-1
11
hk-ii
10
expression
9
normal tissue
8
clinicopathological characteristics
8
characteristics prognosis
8
hk-ii expression
8

Similar Publications

Article Synopsis
  • - This study evaluated the expression of glucose transporter (GLUT)-1 and hexokinase (HK)-II in vocal cord leukoplakia (VCL) and explored its clinical importance using samples from various throat conditions over a four-year period.
  • - Results showed significant differences in factors like sex and smoking between VCL and vocal cord polyp patients, with GLUT-1 and HK-II expressions being higher in laryngeal carcinoma cases, particularly in severe dysplasia.
  • - Both GLUT-1 and HK-II levels increased with the severity of dysplasia, indicating that their expression could serve as biomarkers for assessing the progression of VCL and its potential transformation to cancer.
View Article and Find Full Text PDF

Value of glucose transport protein 1 expression in detecting lymph node metastasis in patients with colorectal cancer.

World J Clin Cases

February 2024

Department of Internal Medicen, Chungbuk National University, College of medicine, Cheongju-si 28644, South Korea.

Article Synopsis
  • A study was conducted to assess GLUT-1, GLUT-3, HK-II, and HIF-1 as potential biomarkers for predicting lymph node metastasis in colorectal cancer patients, in conjunction with 18F-FDG-PET/CT imaging.
  • The research involved 169 patients who underwent surgery and PET/CT; findings showed GLUT-1 was expressed in 64.5% of tumors and had a strong correlation with higher PET/CT SUVmax values for both primary tumors and lymph nodes.
  • The study concluded that GLUT-1 positivity enhances the sensitivity of PET/CT for detecting lymph node metastasis, while GLUT-3, HK-II, and HIF-1 did not
View Article and Find Full Text PDF

Regulation of Glycolysis in Head and Neck Cancer.

Adv Exp Med Biol

April 2021

Amity Institute of Molecular Medicine & Stem Cell Research, Amity University, Noida, Uttar Pradesh, India.

Head and neck squamous cell carcinoma (HNSCC) glycolysis is an important factor for the advancement of the disease and metastasis. Upregulation of glycolysis leads to decreased sensitivity to chemotherapy and radiation. HNSCC cells maintain constitutive glycolytic flux generating metabolic intermediates for the synthesis of amino acids, nucleotides, and fats for cell survival and disease progression.

View Article and Find Full Text PDF

Papillary craniopharyngiomas are characterized by the BRAF V600E mutation. Enhancement of glucose metabolism may be involved in the downstream of the BRAF V600E mutation in many types of tumors. Glucose metabolism was investigated in craniopharyngioma using immunohistochemical analysis.

View Article and Find Full Text PDF

PD-L1 in Lung Adenocarcinoma: Insights into the Role of F-FDG PET/CT.

Cancer Manag Res

July 2020

Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

Purpose: This study aimed to evaluate the role of F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/computed tomography (CT) in expression of tumor programmed death ligand-1 (PD-L1) expression and prognostic significance of F-FDG PET/CT at different PD-L1 status in patients with lung adenocarcinoma.

Patients And Methods: Seventy-three patients with primary lung adenocarcinoma who received F-FDG PET/CT before treatment were retrospectively included in this study. Expression of tumor PD-L1, programmed death-1 (PD-1) and glucose metabolic parameters were evaluated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!